Spotlight on NLRP3 Inflammasome: Role in Pathogenesis and Therapies of Atherosclerosis

References

• Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol. 2015;12(9):508–530. doi:10.1038/nrcardio.2015.82
   PubMed Web of Science ®Google Scholar
• Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116. doi:10.1038/nri3793
   PubMed Web of Science ®Google Scholar
• Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015;116(2):307–311. doi:10.1161/CIRCRESAHA.116.301313
   PubMed Web of Science ®Google Scholar
• Kim YK, Shin JS, Nahm MH. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J. 2016;57(1):5–14. doi:10.3349/ymj.2016.57.1.5
   PubMed Web of Science ®Google Scholar
• Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4(3):a006049–a006049. doi:10.1101/cshperspect.a006049
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820. doi:10.1016/j.cell.2010.01.022
   PubMed Web of Science ®Google Scholar
• Subramanian N, Natarajan K, Clatworthy MR, Wang Z, Germain RN. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell. 2013;153(2):348–361. doi:10.1016/j.cell.2013.02.054
   PubMed Web of Science ®Google Scholar
• Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122(12):1722–1740. doi:10.1161/CIRCRESAHA.118.311362
   PubMed Web of Science ®Google Scholar
• Hoseini Z, Sepahvand F, Rashidi B, Sahebkar A, Masoudifar A, Mirzaei H. NLRP3 inflammasome: its regulation and involvement in atherosclerosis. J Cell Physiol. 2018;233(3):2116–2132. doi:10.1002/jcp.25930
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–832. doi:10.1016/j.cell.2010.01.040
   PubMed Web of Science ®Google Scholar
• Cai X, Chen J, Xu H, et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell. 2014;156(6):1207–1222. doi:10.1016/j.cell.2014.01.063
   PubMed Web of Science ®Google Scholar
• Li Y, Fu TM, Lu A, et al. Cryo-EM structures of ASC and NLRC4 CARD filaments reveal a unified mechanism of nucleation and activation of caspase-1. Proc Natl Acad Sci U S A. 2018;115(43):10845–10852. doi:10.1073/pnas.1810524115
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–665. doi:10.1038/nature15514
   PubMed Web of Science ®Google Scholar
• Kesavardhana S, Kanneganti TD. Mechanisms governing inflammasome activation, assembly and pyroptosis induction. Int Immunol. 2017;29(5):201–210. doi:10.1093/intimm/dxx018
   PubMed Web of Science ®Google Scholar
• McKee CM, Coll RC. NLRP3 inflammasome priming: a riddle wrapped in a mystery inside an enigma. J Leukoc Biol. 2020;108(3):937–952. doi:10.1002/JLB.3MR0720-513R
   PubMed Web of Science ®Google Scholar
• Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787–791. doi:10.4049/jimmunol.0901363
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Kanneganti TD. Nlrp3: an immune sensor of cellular stress and infection. Int J Biochem Cell Biol. 2010;42(6):792–795. doi:10.1016/j.biocel.2010.01.008
   PubMed Web of Science ®Google Scholar
• Muñoz-Planillo R, Kuffa P, Martínez-Colón G, Smith BL, Rajendiran TM, Núñez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38(6):1142–1153. doi:10.1016/j.immuni.2013.05.016
   PubMed Web of Science ®Google Scholar
• Lee GS, Subramanian N, Kim AI, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492(7427):123–127. doi:10.1038/nature11588
   PubMed Web of Science ®Google Scholar
• Green JP, Yu S, Martín-Sánchez F, et al. Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proc Natl Acad Sci U S A. 2018;115(40):E9371–e9380. doi:10.1073/pnas.1812744115
   PubMed Web of Science ®Google Scholar
• Scambler T, Jarosz-Griffiths HH, Lara-Reyna S, et al. ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. eLife. 2019;8. doi:10.7554/eLife.49248
   Web of Science ®Google Scholar
• He Y, Zeng MY, Yang D, Motro B, Núñez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530(7590):354–357. doi:10.1038/nature16959
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440(7081):228–232. doi:10.1038/nature04515
   PubMed Web of Science ®Google Scholar
• Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994;269(21):15195–15203. doi:10.1016/S0021-9258(17)36591-2
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Lamkanfi M, Kim YG, et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity. 2007;26(4):433–443. doi:10.1016/j.immuni.2007.03.008
   PubMed Web of Science ®Google Scholar
• Walev I, Reske K, Palmer M, Valeva A, Bhakdi S. Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J. 1995;14(8):1607–1614. doi:10.1002/j.1460-2075.1995.tb07149.x
   PubMed Web of Science ®Google Scholar
• Di A, Xiong S, Ye Z, et al. The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation. Immunity. 2018;49(1):56–65.e54. doi:10.1016/j.immuni.2018.04.032
   PubMed Web of Science ®Google Scholar
• Shi H, Wang Y, Li X, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016;17(3):250–258. doi:10.1038/ni.3333
   PubMed Web of Science ®Google Scholar
• Samir P, Kesavardhana S, Patmore DM, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature. 2019;573(7775):590–594. doi:10.1038/s41586-019-1551-2
   PubMed Web of Science ®Google Scholar
• Groß CJ, Mishra R, Schneider KS, et al. K(+) efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. Immunity. 2016;45(4):761–773. doi:10.1016/j.immuni.2016.08.010
   PubMed Web of Science ®Google Scholar
• Sanman LE, Qian Y, Eisele NA, et al. Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death. eLife. 2016;5:e13663. doi:10.7554/eLife.13663
   PubMed Web of Science ®Google Scholar
• Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity. 2009;30(6):860–874. doi:10.1016/j.immuni.2009.04.012
   PubMed Web of Science ®Google Scholar
• Murakami T, Ockinger J, Yu J, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2012;109(28):11282–11287. doi:10.1073/pnas.1117765109
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Hughes TR, Triantafilou M, Morgan BP. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci. 2013;126(Pt 13):2903–2913. doi:10.1242/jcs.124388
   PubMed Web of Science ®Google Scholar
• Rossol M, Pierer M, Raulien N, et al. Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun. 2012;3:1329. doi:10.1038/ncomms2339
   PubMed Web of Science ®Google Scholar
• Lebeaupin C, Proics E, de Bieville CH, et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis. 2015;6(9):e1879. doi:10.1038/cddis.2015.248
   PubMedGoogle Scholar
• Compan V, Baroja-Mazo A, López-Castejón G, et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity. 2012;37(3):487–500. doi:10.1016/j.immuni.2012.06.013
   PubMed Web of Science ®Google Scholar
• Yaron JR, Gangaraju S, Rao MY, et al. K(+) regulates Ca(2+) to drive inflammasome signaling: dynamic visualization of ion flux in live cells. Cell Death Dis. 2015;6(10):e1954. doi:10.1038/cddis.2015.277
   PubMedGoogle Scholar
• Katsnelson MA, Rucker LG, Russo HM, Dubyak GR. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol. 2015;194(8):3937–3952. doi:10.4049/jimmunol.1402658
   PubMed Web of Science ®Google Scholar
• Feraille E, Dizin E. Coordinated control of ENaC and Na+, K+-ATPase in renal collecting duct. J Am Soc Nephrol. 2016;27(9):2554–2563. doi:10.1681/ASN.2016020124
   PubMed Web of Science ®Google Scholar
• Verhoef PA, Kertesy SB, Lundberg K, Kahlenberg JM, Dubyak GR. Inhibitory effects of chloride on the activation of caspase-1, IL-1beta secretion, and cytolysis by the P2X7 receptor. J Immunol. 2005;175(11):7623–7634. doi:10.4049/jimmunol.175.11.7623
   PubMed Web of Science ®Google Scholar
• Daniels MJ, Rivers-Auty J, Schilling T, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun. 2016;7:12504. doi:10.1038/ncomms12504
   PubMed Web of Science ®Google Scholar
• Tang T, Lang X, Xu C, et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun. 2017;8(1):202. doi:10.1038/s41467-017-00227-x
   PubMed Web of Science ®Google Scholar
• Cruz CM, Rinna A, Forman HJ, Ventura AL, Persechini PM, Ojcius DM. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem. 2007;282(5):2871–2879. doi:10.1074/jbc.M608083200
   PubMed Web of Science ®Google Scholar
• Zhong Z, Zhai Y, Liang S, et al. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun. 2013;4:1611. doi:10.1038/ncomms2608
   PubMed Web of Science ®Google Scholar
• Sarkar S, Malovic E, Harishchandra DS, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease. NPJ Parkinson’s Dis. 2017;3:30. doi:10.1038/s41531-017-0032-2
   PubMed Web of Science ®Google Scholar
• Jabaut J, Ather JL, Taracanova A, Poynter ME, Ckless K. Mitochondria-targeted drugs enhance Nlrp3 inflammasome-dependent IL-1β secretion in association with alterations in cellular redox and energy status. Free Radic Biol Med. 2013;60:233–245. doi:10.1016/j.freeradbiomed.2013.01.025
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–107. doi:10.1038/nature08780
   PubMed Web of Science ®Google Scholar
• Lemasters JJ, Theruvath TP, Zhong Z, Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta. 2009;1787(11):1395–1401. doi:10.1016/j.bbabio.2009.06.009
   PubMed Web of Science ®Google Scholar
• Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3):222–230. doi:10.1038/ni.1980
   PubMed Web of Science ®Google Scholar
• Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36(3):401–414. doi:10.1016/j.immuni.2012.01.009
   PubMed Web of Science ®Google Scholar
• Han Y, Xu X, Tang C, et al. Reactive oxygen species promote tubular injury in diabetic nephropathy: the role of the mitochondrial ros-txnip-nlrp3 biological axis. Redox Biol. 2018;16:32–46. doi:10.1016/j.redox.2018.02.013
   PubMed Web of Science ®Google Scholar
• Dashdorj A, Jyothi KR, Lim S, et al. Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC Med. 2013;11:178. doi:10.1186/1741-7015-11-178
   PubMed Web of Science ®Google Scholar
• Zu Y, Wan LJ, Cui SY, Gong YP, Li CL. The mitochondrial Na(+)/Ca(2+) exchanger may reduce high glucose-induced oxidative stress and nucleotide-binding oligomerization domain receptor 3 inflammasome activation in endothelial cells. J Geriatr Cardiol. 2015;12(3):270–278. doi:10.11909/j.issn.1671-5411.2015.03.003
   PubMedGoogle Scholar
• Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136–140. doi:10.1038/ni.1831
   PubMed Web of Science ®Google Scholar
• Iyer SS, He Q, Janczy JR, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity. 2013;39(2):311–323. doi:10.1016/j.immuni.2013.08.001
   PubMed Web of Science ®Google Scholar
• Dagvadorj J, Mikulska-Ruminska K, Tumurkhuu G, et al. Recruitment of pro-IL-1α to mitochondrial cardiolipin, via shared LC3 binding domain, inhibits mitophagy and drives maximal NLRP3 activation. Proc Natl Acad Sci U S A. 2021;118(1). doi:10.1073/pnas.2015632118
   PubMed Web of Science ®Google Scholar
• Park S, Juliana C, Hong S, et al. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol. 2013;191(8):4358–4366. doi:10.4049/jimmunol.1301170
   PubMed Web of Science ®Google Scholar
• Campden RI, Zhang Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. Arch Biochem Biophys. 2019;670:32–42. doi:10.1016/j.abb.2019.02.015
   PubMed Web of Science ®Google Scholar
• Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847–856. doi:10.1038/ni.1631
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19(1):57–64. doi:10.1038/nm.2999
   PubMed Web of Science ®Google Scholar
• Orlowski GM, Colbert JD, Sharma S, Bogyo M, Robertson SA, Rock KL. Multiple cathepsins promote Pro-IL-1β synthesis and NLRP3-mediated IL-1β activation. J Immunol. 2015;195(4):1685–1697. doi:10.4049/jimmunol.1500509
   PubMed Web of Science ®Google Scholar
• Oleszycka E, Moran HB, Tynan GA, et al. IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. FEBS J. 2016;283(1):9–24. doi:10.1111/febs.13546
   PubMed Web of Science ®Google Scholar
• Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59(9):1192–1199. doi:10.1136/gut.2009.197822
   PubMed Web of Science ®Google Scholar
• Edye ME, Lopez-Castejon G, Allan SM, Brough D. Acidosis drives damage-associated molecular pattern (DAMP)-induced interleukin-1 secretion via a caspase-1-independent pathway. J Biol Chem. 2013;288(42):30485–30494. doi:10.1074/jbc.M113.478941
   PubMed Web of Science ®Google Scholar
• Katsnelson MA, Lozada-Soto KM, Russo HM, Miller BA, Dubyak GR. NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx. Am J Physiol Cell Physiol. 2016;311(1):C83–c100. doi:10.1152/ajpcell.00298.2015
   PubMed Web of Science ®Google Scholar
• Tseng HHL, Vong CT, Kwan YW, Lee SM, Hoi MPM. Lysosomal Ca(2+) signaling regulates high glucose-mediated interleukin-1β secretion via transcription factor EB in human monocytic cells. Front Immunol. 2017;8:1161. doi:10.3389/fimmu.2017.01161
   PubMed Web of Science ®Google Scholar
• Zhang Z, Meszaros G, He WT, et al. Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J Exp Med. 2017;214(9):2671–2693. doi:10.1084/jem.20162040
   PubMed Web of Science ®Google Scholar
• Hong S, Hwang I, Gim E, et al. Brefeldin A-sensitive ER-Golgi vesicle trafficking contributes to NLRP3-dependent caspase-1 activation. FASEB J. 2019;33(3):4547–4558. doi:10.1096/fj.201801585R
   PubMed Web of Science ®Google Scholar
• Guo C, Chi Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity. 2018;49(5):842–856.e847. doi:10.1016/j.immuni.2018.08.021
   PubMed Web of Science ®Google Scholar
• Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature. 2018;564(7734):71–76. doi:10.1038/s41586-018-0761-3
   PubMed Web of Science ®Google Scholar
• Geng J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep. 2008;9(9):859–864. doi:10.1038/embor.2008.163
   PubMed Web of Science ®Google Scholar
• Weidberg H, Shvets E, Elazar Z. Biogenesis and cargo selectivity of autophagosomes. Annu Rev Biochem. 2011;80:125–156. doi:10.1146/annurev-biochem-052709-094552
   PubMed Web of Science ®Google Scholar
• Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 2008;456(7219):264–268. doi:10.1038/nature07383
   PubMed Web of Science ®Google Scholar
• Liu P, Huang G, Wei T, et al. Sirtuin 3-induced macrophage autophagy in regulating NLRP3 inflammasome activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864(3):764–777. doi:10.1016/j.bbadis.2017.12.027
   PubMed Web of Science ®Google Scholar
• Cho MH, Cho K, Kang HJ, et al. Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy. 2014;10(10):1761–1775. doi:10.4161/auto.29647
   PubMed Web of Science ®Google Scholar
• Nurmi K, Kareinen I, Virkanen J, et al. Hemin and cobalt protoporphyrin inhibit NLRP3 inflammasome activation by enhancing autophagy: a novel mechanism of inflammasome regulation. J Innate Immun. 2017;9(1):65–82. doi:10.1159/000448894
   PubMed Web of Science ®Google Scholar
• Spalinger MR, Lang S, Gottier C, et al. PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. Autophagy. 2017;13(9):1590–1601. doi:10.1080/15548627.2017.1341453
   PubMed Web of Science ®Google Scholar
• Kim MJ, Bae SH, Ryu JC, et al. SESN2/sestrin2 suppresses sepsis by inducing mitophagy and inhibiting NLRP3 activation in macrophages. Autophagy. 2016;12(8):1272–1291. doi:10.1080/15548627.2016.1183081
   PubMed Web of Science ®Google Scholar
• Houtman J, Freitag K, Gimber N, Schmoranzer J, Heppner FL, Jendrach M. Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3. EMBO J. 2019;38(4). doi:10.15252/embj.201899430
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang L, Shi L, et al. Zearalenone induces NLRP3-dependent pyroptosis via activation of NF-κB modulated by autophagy in INS-1 cells. Toxicology. 2019;428:152304. doi:10.1016/j.tox.2019.152304
   PubMed Web of Science ®Google Scholar
• Jiang C, Jiang L, Li Q, et al. Acrolein induces NLRP3 inflammasome-mediated pyroptosis and suppresses migration via ROS-dependent autophagy in vascular endothelial cells. Toxicology. 2018;410:26–40. doi:10.1016/j.tox.2018.09.002
   PubMed Web of Science ®Google Scholar
• Jiang L, Luo S, Qiu T, et al. Bidirectional role of reactive oxygen species during inflammasome activation in acrolein-induced human EAhy926 cells pyroptosis. Toxicol Mech Methods. 2021;31:680–689.
   PubMed Web of Science ®Google Scholar
• Vu LD, Gevaert K, De Smet I. Protein language: post-translational modifications talking to each other. Trends Plant Sci. 2018;23(12):1068–1080. doi:10.1016/j.tplants.2018.09.004
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng X, Li X, et al. Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators. Biochem Pharmacol. 2020;175:113863. doi:10.1016/j.bcp.2020.113863
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. doi:10.1038/s41577-019-0165-0
   PubMed Web of Science ®Google Scholar
• Spalinger MR, Kasper S, Gottier C, et al. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J Clin Invest. 2016;126(5):1783–1800. doi:10.1172/JCI83669
   PubMed Web of Science ®Google Scholar
• Stutz A, Kolbe CC, Stahl R, et al. NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain. J Exp Med. 2017;214(6):1725–1736. doi:10.1084/jem.20160933
   PubMed Web of Science ®Google Scholar
• Martin BN, Wang C, Willette-Brown J, et al. IKKα negatively regulates ASC-dependent inflammasome activation. Nat Commun. 2014;5:4977. doi:10.1038/ncomms5977
   PubMed Web of Science ®Google Scholar
• Song N, Liu ZS, Xue W, et al. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol Cell. 2017;68(1):185–197.e186. doi:10.1016/j.molcel.2017.08.017
   PubMed Web of Science ®Google Scholar
• Hara H, Tsuchiya K, Kawamura I, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol. 2013;14(12):1247–1255. doi:10.1038/ni.2749
   PubMed Web of Science ®Google Scholar
• Lin YC, Huang DY, Wang JS, et al. Syk is involved in NLRP3 inflammasome-mediated caspase-1 activation through adaptor ASC phosphorylation and enhanced oligomerization. J Leukoc Biol. 2015;97(5):825–835. doi:10.1189/jlb.3HI0814-371RR
   PubMed Web of Science ®Google Scholar
• Chung IC, OuYang CN, Yuan SN, et al. Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Sci Rep. 2016;6:36214. doi:10.1038/srep36214
   PubMed Web of Science ®Google Scholar
• Mambwe B, Neo K, Javanmard Khameneh H, et al. Tyrosine dephosphorylation of ASC modulates the activation of the NLRP3 and AIM2 inflammasomes. Front Immunol. 2019;10:1556. doi:10.3389/fimmu.2019.01556
   PubMed Web of Science ®Google Scholar
• Basak C, Pathak SK, Bhattacharyya A, Mandal D, Pathak S, Kundu M. NF-kappaB- and C/EBPbeta-driven interleukin-1beta gene expression and PAK1-mediated caspase-1 activation play essential roles in interleukin-1beta release from Helicobacter pylori lipopolysaccharide-stimulated macrophages. J Biol Chem. 2005;280(6):4279–4288. doi:10.1074/jbc.M412820200
   PubMed Web of Science ®Google Scholar
• Zhang A, Xing J, Xia T, et al. EphA2 phosphorylates NLRP3 and inhibits inflammasomes in airway epithelial cells. EMBO Rep. 2020;21(7):e49666. doi:10.15252/embr.201949666
   PubMed Web of Science ®Google Scholar
• Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat Immunol. 2016;17(10):1176–1186. doi:10.1038/ni.3538
   PubMed Web of Science ®Google Scholar
• Guo C, Xie S, Chi Z, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. 2016;45(4):802–816. doi:10.1016/j.immuni.2016.09.008
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lu M, Du RH, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener. 2016;11:28. doi:10.1186/s13024-016-0094-3
   PubMed Web of Science ®Google Scholar
• Li XF, Shen WW, Sun YY, et al. MicroRNA-20a negatively regulates expression of NLRP3-inflammasome by targeting TXNIP in adjuvant-induced arthritis fibroblast-like synoviocytes. Joint Bone Spine. 2016;83(6):695–700. doi:10.1016/j.jbspin.2015.10.007
   PubMed Web of Science ®Google Scholar
• Wang Y, Han Z, Fan Y, et al. MicroRNA-9 inhibits NLRP3 inflammasome activation in human atherosclerosis inflammation cell models through the JAK1/STAT signaling pathway. Cell Physiol Biochem. 2017;41(4):1555–1571. doi:10.1159/000470822
   PubMedGoogle Scholar
• Yin R, Zhu X, Wang J, et al. MicroRNA-155 promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the ERK1/2 pathway in THP-1 macrophages and aggravates atherosclerosis in ApoE-/- mice. Ann Palliat Med. 2019;8(5):676–689. doi:10.21037/apm.2019.10.11
   PubMed Web of Science ®Google Scholar
• Li P, Zhong X, Li J, et al. MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis. Biochem Biophys Res Commun. 2018;503(4):2833–2840. doi:10.1016/j.bbrc.2018.08.049
   PubMed Web of Science ®Google Scholar
• Song J, Yang S, Yin R, Xiao Q, Ma A, Pan X. MicroRNA-181a regulates the activation of the NLRP3 inflammatory pathway by targeting MEK1 in THP-1 macrophages stimulated by ox-LDL. J Cell Biochem. 2019;120(8):13640–13650. doi:10.1002/jcb.28637
   PubMed Web of Science ®Google Scholar
• Xu X, Yang Y, Wang G, et al. Low shear stress regulates vascular endothelial cell pyroptosis through miR-181b-5p/STAT-3 axis. J Cell Physiol. 2021;236(1):318–327. doi:10.1002/jcp.29844
   PubMed Web of Science ®Google Scholar
• Chen M, Li W, Zhang Y, Yang J. MicroRNA-20a protects human aortic endothelial cells from Ox-LDL-induced inflammation through targeting TLR4 and TXNIP signaling. Biomed Pharmacother. 2018;103:191–197. doi:10.1016/j.biopha.2018.03.129
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479(7371):117–121. doi:10.1038/nature10558
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. 2014;514(7521):187–192. doi:10.1038/nature13683
   PubMed Web of Science ®Google Scholar
• Yang D, He Y, Muñoz-Planillo R, Liu Q, Núñez G. Caspase-11 requires the Pannexin-1 channel and the Purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity. 2015;43(5):923–932. doi:10.1016/j.immuni.2015.10.009
   PubMed Web of Science ®Google Scholar
• He Y, Franchi L, Núñez G. TLR agonists stimulate Nlrp3-dependent IL-1β production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol. 2013;190(1):334–339. doi:10.4049/jimmunol.1202737
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell. 2012;150(3):606–619. doi:10.1016/j.cell.2012.07.007
   PubMed Web of Science ®Google Scholar
• Gurung P, Malireddi RK, Anand PK, et al. Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-β (TRIF)-mediated caspase-11 protease production integrates Toll-like receptor 4 (TLR4) protein- and Nlrp3 inflammasome-mediated host defense against enteropathogens. J Biol Chem. 2012;287(41):34474–34483. doi:10.1074/jbc.M112.401406
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165(4):792–800. doi:10.1016/j.cell.2016.03.046
   PubMed Web of Science ®Google Scholar
• Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34(2):213–223. doi:10.1016/j.immuni.2011.02.006
   PubMed Web of Science ®Google Scholar
• Zanoni I, Tan Y, Di Gioia M, et al. An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science (New York, NY). 2016;352(6290):1232–1236. doi:10.1126/science.aaf3036
   Google Scholar
• Chu LH, Indramohan M, Ratsimandresy RA, et al. The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun. 2018;9(1):996. doi:10.1038/s41467-018-03409-3
   PubMedGoogle Scholar
• Li W, Zhang W, Deng M, et al. Stearoyl lysophosphatidylcholine inhibits endotoxin-induced Caspase-11 activation. Shock (Augusta, Ga). 2018;50(3):339–345. doi:10.1097/SHK.0000000000001012
   PubMed Web of Science ®Google Scholar
• Zasłona Z, Flis E, Wilk MM, et al. Caspase-11 promotes allergic airway inflammation. Nat Commun. 2020;11(1):1055. doi:10.1038/s41467-020-14945-2
   PubMed Web of Science ®Google Scholar
• Piccini A, Carta S, Tassi S, Lasiglié D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A. 2008;105(23):8067–8072. doi:10.1073/pnas.0709684105
   PubMed Web of Science ®Google Scholar
• Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009;113(10):2324–2335. doi:10.1182/blood-2008-03-146720
   PubMed Web of Science ®Google Scholar
• Gaidt MM, Ebert TS, Chauhan D, et al. Human monocytes engage an alternative inflammasome pathway. Immunity. 2016;44(4):833–846. doi:10.1016/j.immuni.2016.01.012
   PubMed Web of Science ®Google Scholar
• Zewinger S, Reiser J, Jankowski V, et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol. 2020;21(1):30–41. doi:10.1038/s41590-019-0548-1
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–1361. doi:10.1038/nature08938
   PubMed Web of Science ®Google Scholar
• Mehta S, Dhawan V. Exposure of cigarette smoke condensate activates NLRP3 inflammasome in THP-1 cells in a stage-specific manner: an underlying role of innate immunity in atherosclerosis. Cell Signal. 2020;72:109645. doi:10.1016/j.cellsig.2020.109645
   PubMed Web of Science ®Google Scholar
• Wen C, Yang X, Yan Z, et al. Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification. Int J Cardiol. 2013;168(3):2242–2247. doi:10.1016/j.ijcard.2013.01.211
   PubMed Web of Science ®Google Scholar
• Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16(8):1000–1006. doi:10.1161/01.ATV.16.8.1000
   PubMed Web of Science ®Google Scholar
• Bhaskar V, Yin J, Mirza AM, et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis. 2011;216(2):313–320. doi:10.1016/j.atherosclerosis.2011.02.026
   PubMed Web of Science ®Google Scholar
• Gomez D, Baylis RA, Durgin BG, et al. Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat Med. 2018;24(9):1418–1429. doi:10.1038/s41591-018-0124-5
   PubMed Web of Science ®Google Scholar
• Hendrikx T, Jeurissen ML, van Gorp PJ, et al. Bone marrow-specific caspase-1/11 deficiency inhibits atherosclerosis development in Ldlr(-/-) mice. FEBS J. 2015;282(12):2327–2338. doi:10.1111/febs.13279
   PubMed Web of Science ®Google Scholar
• Zheng F, Xing S, Gong Z, Xing Q. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ. 2013;22(9):746–750. doi:10.1016/j.hlc.2013.01.012
   PubMed Web of Science ®Google Scholar
• Shi X, Xie WL, Kong WW, Chen D, Qu P. Expression of the NLRP3 inflammasome in carotid atherosclerosis. J Stroke Cerebrovasc Dis. 2015;24(11):2455–2466. doi:10.1016/j.jstrokecerebrovasdis.2015.03.024
   PubMed Web of Science ®Google Scholar
• Paramel Varghese G, Folkersen L, Strawbridge RJ, et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc. 2016;5(5). doi:10.1161/JAHA.115.003031
   PubMed Web of Science ®Google Scholar
• Schunk SJ, Kleber ME, März W, et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021;42(18):1742–1756. doi:10.1093/eurheartj/ehab107
   PubMed Web of Science ®Google Scholar
• Zhao X, Gu C, Yan C, et al. NALP3-inflammasome-related gene polymorphisms in patients with prehypertension and coronary atherosclerosis. Biomed Res Int. 2016;2016:7395627. doi:10.1155/2016/7395627
   PubMed Web of Science ®Google Scholar
• Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22(6):423–436. doi:10.1002/dmrr.634
   PubMed Web of Science ®Google Scholar
• Peng Z, Shu B, Zhang Y, Wang M. Endothelial response to pathophysiological stress. Arterioscler Thromb Vasc Biol. 2019;39(11):e233–e243. doi:10.1161/ATVBAHA.119.312580
   PubMed Web of Science ®Google Scholar
• Klein CL, Köhler H, Kirkpatrick CJ. Increased adhesion and activation of polymorphonuclear neutrophil granulocytes to endothelial cells under heavy metal exposure in vitro. Pathobiology. 1994;62(2):90–98. doi:10.1159/000163883
   PubMed Web of Science ®Google Scholar
• Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713–735. doi:10.1161/CIRCRESAHA.116.309326
   PubMed Web of Science ®Google Scholar
• Sheikine Y, Sirsjö A. CXCL16/SR-PSOX–a friend or a foe in atherosclerosis? Atherosclerosis. 2008;197(2):487–495. doi:10.1016/j.atherosclerosis.2007.11.034
   PubMed Web of Science ®Google Scholar
• Xiao H, Lu M, Lin TY, et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation. 2013;128(6):632–642. doi:10.1161/CIRCULATIONAHA.113.002714
   PubMed Web of Science ®Google Scholar
• Chien CS, Li JY, Chien Y, et al. METTL3-dependent N(6)-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A. 2021;118(7). doi:10.1073/pnas.2025070118
   Web of Science ®Google Scholar
• Koka S, Xia M, Chen Y, et al. Endothelial NLRP3 inflammasome activation and arterial neointima formation associated with acid sphingomyelinase during hypercholesterolemia. Redox Biol. 2017;13:336–344. doi:10.1016/j.redox.2017.06.004
   PubMed Web of Science ®Google Scholar
• Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575–585. doi:10.1016/j.cmet.2011.07.015
   PubMed Web of Science ®Google Scholar
• Yin Y, Li X, Sha X, et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol. 2015;35(4):804–816. doi:10.1161/ATVBAHA.115.305282
   PubMed Web of Science ®Google Scholar
• Lin TY, Wei TW, Li S, et al. TIFA as a crucial mediator for NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2016;113(52):15078–15083. doi:10.1073/pnas.1618773114
   PubMed Web of Science ®Google Scholar
• Hang L, Peng Y, Xiang R, Li X, Li Z. Ox-LDL causes endothelial cell injury through ASK1/NLRP3-mediated inflammasome activation via endoplasmic reticulum stress. Drug Des Devel Ther. 2020;14:731–744. doi:10.2147/DDDT.S231916
   PubMed Web of Science ®Google Scholar
• Huang D, Gao W, Zhong X, Ge J. NLRP3 activation in endothelia promotes development of diabetes-associated atherosclerosis. Aging. 2020;12(18):18181–18191. doi:10.18632/aging.103666
   PubMedGoogle Scholar
• Zhang Y, Li X, Pitzer AL, Chen Y, Wang L, Li PL. Coronary endothelial dysfunction induced by nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3 inflammasome activation during hypercholesterolemia: beyond inflammation. Antioxid Redox Signal. 2015;22(13):1084–1096. doi:10.1089/ars.2014.5978
   PubMed Web of Science ®Google Scholar
• Wang J, Shen X, Liu J, et al. High glucose mediates NLRP3 inflammasome activation via upregulation of ELF3 expression. Cell Death Dis. 2020;11(5):383. doi:10.1038/s41419-020-2598-6
   PubMed Web of Science ®Google Scholar
• Zhaolin Z, Jiaojiao C, Peng W, et al. OxLDL induces vascular endothelial cell pyroptosis through miR-125a-5p/TET2 pathway. J Cell Physiol. 2019;234(5):7475–7491. doi:10.1002/jcp.27509
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang H, Qi W, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018;9(2):171. doi:10.1038/s41419-017-0257-3
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen Y, Zhang Y, Li PL, Li X. Contribution of cathepsin B-dependent Nlrp3 inflammasome activation to nicotine-induced endothelial barrier dysfunction. Eur J Pharmacol. 2019;865:172795. doi:10.1016/j.ejphar.2019.172795
   PubMed Web of Science ®Google Scholar
• Cao X, Wang S, Bi R, Tian S, Huo Y, Liu J. Toxic effects of Cr(VI) on the bovine hemoglobin and human vascular endothelial cells: molecular interaction and cell damage. Chemosphere. 2019;222:355–363. doi:10.1016/j.chemosphere.2019.01.137
   PubMed Web of Science ®Google Scholar
• Chen H, Lu Y, Cao Z, et al. Cadmium induces NLRP3 inflammasome-dependent pyroptosis in vascular endothelial cells. Toxicol Lett. 2016;246:7–16. doi:10.1016/j.toxlet.2016.01.014
   PubMed Web of Science ®Google Scholar
• Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc. 2017;6(9). doi:10.1161/JAHA.117.006347
   Web of Science ®Google Scholar
• Liu Y, Zhang HG. Vigilance on new-onset atherosclerosis following SARS-CoV-2 infection. Front Med. 2020;7:629413. doi:10.3389/fmed.2020.629413
   Web of Science ®Google Scholar
• Wang JG, Williams JC, Davis BK, et al. Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood. 2011;118(8):2366–2374. doi:10.1182/blood-2011-01-330878
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126. doi:10.1056/NEJM199901143400207
   PubMed Web of Science ®Google Scholar
• Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–197. doi:10.1146/annurev.immunol.021908.132620
   PubMed Web of Science ®Google Scholar
• Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. Immunity. 2017;47(4):621–634. doi:10.1016/j.immuni.2017.09.008
   PubMed Web of Science ®Google Scholar
• Mao C, Li D, Zhou E, Zhang J, Wang C, Xue C. Nicotine exacerbates atherosclerosis through a macrophage-mediated endothelial injury pathway. Aging. 2021;13(5):7627–7643. doi:10.18632/aging.202660
   PubMedGoogle Scholar
• Mehta S, Dhawan V. Molecular insights of cigarette smoke condensate-activated NLRP3 inflammasome in THP-1 cells in a stage-specific atherogenesis. Int Immunopharmacol. 2020;88:107013. doi:10.1016/j.intimp.2020.107013
   PubMed Web of Science ®Google Scholar
• Buscetta M, Di Vincenzo S, Miele M, Badami E, Pace E, Cipollina C. Cigarette smoke inhibits the NLRP3 inflammasome and leads to caspase-1 activation via the TLR4-TRIF-caspase-8 axis in human macrophages. FASEB J. 2020;34(1):1819–1832. doi:10.1096/fj.201901239R
   PubMed Web of Science ®Google Scholar
• Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010;5(7):e11765. doi:10.1371/journal.pone.0011765
   PubMed Web of Science ®Google Scholar
• Westerterp M, Fotakis P, Ouimet M, et al. Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis. Circulation. 2018;138(9):898–912. doi:10.1161/CIRCULATIONAHA.117.032636
   PubMed Web of Science ®Google Scholar
• Peng K, Liu L, Wei D, et al. P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation. Int J Mol Med. 2015;35(5):1179–1188. doi:10.3892/ijmm.2015.2129
   PubMed Web of Science ®Google Scholar
• L’Homme L, Esser N, Riva L, et al. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J Lipid Res. 2013;54(11):2998–3008. doi:10.1194/jlr.M037861
   PubMed Web of Science ®Google Scholar
• Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci. 2012;69(18):2999–3013. doi:10.1007/s00018-012-0962-0
   PubMed Web of Science ®Google Scholar
• Son SJ, Rhee KJ, Lim J, Kim TU, Kim TJ, Kim YS. Triglyceride-induced macrophage cell death is triggered by caspase-1. Biol Pharm Bull. 2013;36(1):108–113. doi:10.1248/bpb.b12-00571
   PubMed Web of Science ®Google Scholar
• Chen S, Lee Y, Crother TR, et al. Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease. Arterioscler Thromb Vasc Biol. 2012;32(8):e60–71. doi:10.1161/ATVBAHA.112.249417
   PubMed Web of Science ®Google Scholar
• Wakita D, Kurashima Y, Crother TR, et al. Role of interleukin-1 signaling in a mouse model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm. Arterioscler Thromb Vasc Biol. 2016;36(5):886–897. doi:10.1161/ATVBAHA.115.307072
   PubMed Web of Science ®Google Scholar
• Campbell LA, Kuo CC. Chlamydia pneumoniae–an infectious risk factor for atherosclerosis? Nat Rev Microbiol. 2004;2(1):23–32. doi:10.1038/nrmicro796
   PubMed Web of Science ®Google Scholar
• Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest. 1999;103(5):747–753. doi:10.1172/JCI4582
   PubMed Web of Science ®Google Scholar
• Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI. Chlamydia pneumoniae–induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect Immun. 2007;75(2):753–759. doi:10.1128/IAI.01386-06
   PubMed Web of Science ®Google Scholar
• Itoh R, Murakami I, Chou B, et al. Chlamydia pneumoniae harness host NLRP3 inflammasome-mediated caspase-1 activation for optimal intracellular growth in murine macrophages. Biochem Biophys Res Commun. 2014;452(3):689–694. doi:10.1016/j.bbrc.2014.08.128
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T, Ando T. Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis. Pathog Dis. 2015;73(4). doi:10.1093/femspd/ftv011
   PubMed Web of Science ®Google Scholar
• Zhang R, Song B, Hong X, Shen Z, Sui L, Wang S. microRNA-9 inhibits vulnerable plaque formation and vascular remodeling via suppression of the SDC2-dependent FAK/ERK signaling pathway in mice with atherosclerosis. Front Physiol. 2020;11:804. doi:10.3389/fphys.2020.00804
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255. doi:10.1038/nm.3806
   PubMed Web of Science ®Google Scholar
• van der Heijden T, Kritikou E, Venema W, et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report. Arterioscler Thromb Vasc Biol. 2017;37(8):1457–1461. doi:10.1161/ATVBAHA.117.309575
   PubMed Web of Science ®Google Scholar
• Sharma A, Choi JSY, Stefanovic N, et al. Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis. Diabetes. 2021;70(3):772–787.
   PubMed Web of Science ®Google Scholar
• Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res. 2015;91:15–28. doi:10.1016/j.phrs.2014.10.009
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiang H, Chen Y, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10(4). doi:10.15252/emmm.201708689
   Web of Science ®Google Scholar
• Guo T, Chen WQ, Zhang C, Zhao YX, Zhang Y. Chymase activity is closely related with plaque vulnerability in a hamster model of atherosclerosis. Atherosclerosis. 2009;207(1):59–67. doi:10.1016/j.atherosclerosis.2009.04.014
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Y, Pan Y, et al. Novel role for tranilast in regulating NLRP3 ubiquitination, vascular inflammation, and atherosclerosis. J Am Heart Assoc. 2020;9(12):e015513. doi:10.1161/JAHA.119.015513
   PubMed Web of Science ®Google Scholar
• MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr Opin Drug Discov Devel. 2010;13(5):568–576.
   PubMedGoogle Scholar
• Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–516. doi:10.1124/jpet.106.111344
   PubMed Web of Science ®Google Scholar
• Zahid A, Li B, Kombe AJK, Jin T, Tao J. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. 2019;10:2538. doi:10.3389/fimmu.2019.02538
   PubMed Web of Science ®Google Scholar
• Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005;12(Suppl 1):942–961. doi:10.1038/sj.cdd.4401556
   PubMedGoogle Scholar
• Bassil F, Fernagut PO, Bezard E, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A. 2016;113(34):9593–9598. doi:10.1073/pnas.1609291113
   PubMed Web of Science ®Google Scholar
• Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther. 2009;11(1):205. doi:10.1186/ar2555
   PubMed Web of Science ®Google Scholar
• Li Y, Niu X, Xu H, et al. VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis. Exp Cell Res. 2020;389(1):111847. doi:10.1016/j.yexcr.2020.111847
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang H, Huang Y, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation. Int Immunopharmacol. 2013;17(1):116–122. doi:10.1016/j.intimp.2013.05.027
   PubMed Web of Science ®Google Scholar
• Irrera N, Vaccaro M, Bitto A, et al. BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clin Sci. 2017;131(6):487–498. doi:10.1042/CS20160645
   Web of Science ®Google Scholar
• Juliana C, Fernandes-Alnemri T, Wu J, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285(13):9792–9802. doi:10.1074/jbc.M109.082305
   PubMed Web of Science ®Google Scholar
• Catalán U, Fernández-Castillejo S, Pons L, et al. Alpha-tocopherol and BAY 11-7082 reduce vascular cell adhesion molecule in human aortic endothelial cells. J Vasc Res. 2012;49(4):319–328. doi:10.1159/000337466
   PubMed Web of Science ®Google Scholar
• Bian F, Yang XY, Xu G, Zheng T, Jin S. CRP-induced NLRP3 inflammasome activation increases LDL transcytosis across endothelial cells. Front Pharmacol. 2019;10:40. doi:10.3389/fphar.2019.00040
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708–722. doi:10.1016/j.autrev.2014.01.058
   PubMed Web of Science ®Google Scholar
• Kaufman MB. FDA approves new rituximab biosimilar & anakinra to treat a rare disease; 2021. Available from: https://www.the-rheumatologist.org/article/fda-approves-new-rituximab-biosimilar-anakinra-to-treat-a-rare-disease/. Accessed December 16, 2021.
   Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;1:Cd005121. doi:10.1002/14651858.CD005121.pub3
   Google Scholar
• Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65:223–244. doi:10.1146/annurev-med-061512-150641
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, Van der meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652. doi:10.1038/nrd3800
   PubMed Web of Science ®Google Scholar
• Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–384. doi:10.1093/eurheartj/ehu272
   PubMed Web of Science ®Google Scholar
• Liu M, Yan M, Lv H, et al. Macrophage K63-linked ubiquitination of YAP promotes its nuclear localization and exacerbates atherosclerosis. Cell Rep. 2020;32(5):107990. doi:10.1016/j.celrep.2020.107990
   PubMed Web of Science ®Google Scholar
• Doss HM, Dey C, Sudandiradoss C, Rasool MK. Targeting inflammatory mediators with ferulic acid, a dietary polyphenol, for the suppression of monosodium urate crystal-induced inflammation in rats. Life Sci. 2016;148:201–210. doi:10.1016/j.lfs.2016.02.004
   PubMed Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. doi:10.1038/nature04516
   PubMed Web of Science ®Google Scholar
• Bauriedel G, Ganesh S, Uberfuhr P, Welsch U, Höfling B. [Growth-inhibiting effect of colchicine on cultured vascular wall myocytes from arteriosclerotic lesions]. Z Kardiol. 1992;81(2):92–98. German.
   PubMedGoogle Scholar
• Cimmino G, Conte S, Morello A, et al. Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. Vascul Pharmacol. 2021;137:106822. doi:10.1016/j.vph.2020.106822
   PubMed Web of Science ®Google Scholar
• Robertson S, Martínez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci. 2016;130(14):1237–1246. doi:10.1042/CS20160090
   Web of Science ®Google Scholar
• Martínez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. doi:10.1161/JAHA.115.002128
   PubMed Web of Science ®Google Scholar
• Peng S, Xu LW, Che XY, et al. Atorvastatin inhibits inflammatory response, attenuates lipid deposition, and improves the stability of vulnerable atherosclerotic plaques by modulating autophagy. Front Pharmacol. 2018;9:438. doi:10.3389/fphar.2018.00438
   PubMed Web of Science ®Google Scholar
• Kong F, Ye B, Lin L, Cai X, Huang W, Huang Z. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytes. Biomed Pharmacother. 2016;82:167–172. doi:10.1016/j.biopha.2016.04.043
   PubMed Web of Science ®Google Scholar
• Altaf A, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. Coron Artery Dis. 2015;26(5):409–421. doi:10.1097/MCA.0000000000000255
   PubMed Web of Science ®Google Scholar
• Boland AJ, Gangadharan N, Kavanagh P, et al. Simvastatin suppresses interleukin Iβ release in human peripheral blood mononuclear cells stimulated with cholesterol crystals. J Cardiovasc Pharmacol Ther. 2018;23(6):509–517.
   PubMed Web of Science ®Google Scholar
• Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047–2058.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61–70. doi:10.1083/jcb.200903124
   PubMed Web of Science ®Google Scholar
• Ling MY, Ma ZY, Wang YY, et al. Up-regulated ATP-sensitive potassium channels play a role in increased inflammation and plaque vulnerability in macrophages. Atherosclerosis. 2013;226(2):348–355. doi:10.1016/j.atherosclerosis.2012.11.016
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214–219. doi:10.1161/01.CIR.0000134501.57864.66
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England). 2006;368(9548):1696–1705. doi:10.1016/S0140-6736(06)69705-5
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018;122(10):1439–1459. doi:10.1161/CIRCRESAHA.117.311588
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10(2):73–84. doi:10.1038/nrcardio.2012.183
   PubMed Web of Science ®Google Scholar
• Dai Y, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther. 2014;28(5):425–432. doi:10.1007/s10557-014-6539-4
   PubMed Web of Science ®Google Scholar
• Marx N, Libby P. Cardiovascular benefits of GLP-1 receptor agonism: is inflammation a key? JACC Basic Transl Sci. 2018;3(6):858–860. doi:10.1016/j.jacbts.2018.11.008
   PubMedGoogle Scholar
• Luo X, Hu Y, He S, et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation. Arch Biochem Biophys. 2019;671:203–209. doi:10.1016/j.abb.2019.07.008
   PubMed Web of Science ®Google Scholar